Frestedt Incorporated is making news!

NEW BOOK JUST RELEASED: Warning Letters – 2016 Reference Guide

February 22, 2016

St. Louis Park, MN – Frestedt Incorporated announces the release of a new book about using warning letters from the FDA to help train staff about how to avoid or recover from a warning letter.

Just in time to celebrate the 8th Anniversary of Frestedt Incorporated (founded on February 26, 2008), Dr. Joy Frestedt announces publication of her first full length text book! With Food and Drug Administration becoming more involved with United States businesses, Warning Letters are issued more often and require immediate response. How to respond and what to do may not be obvious if you’ve never been exposed to a warning letter before. This unique reference book lays out guidelines to learn from the mistakes of others. Readers will understand current trends in Warning Letters, gain insight to real life examples to avoid or to recover and survive and after receiving a Warning Letter.

This 2016 reference guide provides examples of drug and device Warning Letters citing significant deviations from the regulations including:

  • warninglettersFailure to establish appropriate quality systems
  • Failure to document corrective and preventive action plans
  • Failure to maintain appropriate records
    (e.g., complaints, testing, training)
  • Failure to follow clinical trial protocols
    (e.g., subject inclusion/exclusion, deviations)
  • Failure to properly monitor a clinical investigation
  • Inadequate drug or medical device accountability
  • And MANY others!

Warning Letters – 2016 Reference Guide is a great training tool to develop a deeper understanding of topics related to solving regulatory non-compliance issues and business integration plans for drug and device global markets.

To purchase copies of Dr. Frestedt’s Warning Letters – 2016 Reference Guide, please visit Barnett International at: http://www.barnettinternational.com/Publications/Warning-Letters-Reference-Guide–2016-Edition/.

About the Author

Dr. Frestedt is President and CEO of Frestedt Incorporated, a network of highly skilled staff meeting specific needs in regulatory, clinical and quality affairs. Dr. Frestedt has also founded Alimentix, the Minnesota Diet Research Center to run clinical trials for food-related products, non-significant risk devices and over-the-counter drugs. She has more than 35 years of scientific, clinical and regulatory experience in the health care, pharmaceutical, medical device and food-related industries assisting firms with strategic decisions on a global scale. Dr. Frestedt has been named one of the “100 Most Inspiring People in the Life Sciences Industry” by PharmaVOICE and one of the top 25 “Industry Leaders” a “Women in Business Award” by the Minneapolis/St. Paul Business Journal in 2011.

About Frestedt Incorporated

With a holistic, customized approach Frestedt Inc. provides clinical, regulatory, and quality affairs expertise for the biotechnology, food, pharmaceutical and medical device industries. With the ability to help negotiate the ever-changing system of regulations and requirements, Frestedt Incorporated staff can develop customized and cost effective solutions — everything from clinical trial risk based monitoring to successful regulatory negotiations and well-crafted quality system improvements — to support a wide variety of clinical and scientific endeavors.

Contact: Kaitlin Cady, Frestedt Incorporated, (952) 426-1747; info@frestedt.com; www.frestedt.com.

NEW BOOK JUST RELEASED: Warning Letters – 2016 Reference Guide